ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Tempus Introduces AI-enabled Assistant, Tempus One, Into Lens Data Analytics Platform to Accelerate Research

Tempus, a leader in artificial intelligence and precision medicine, today announced the integration of its signature Tempus One technology into its Lens data analytics platform. The AI-enabled Tempus One technology will leverage advancements in generative AI to provide researchers the tools they need to seamlessly analyze Tempus’ de-identified, multimodal data library to glean insights, build patient cohorts, interrogate patient populations, and more.

Tempus One was broadly released to physicians at the 2023 ASCO® Annual Meeting, designed as an AI-enabled clinical assistant that allows rapid and easy queries through voice or typing, leveraging access to their patients’ full clinical and molecular profile, combined with all relevant guidelines for up-to-date standard of care insights. Now, this generative AI technology is being introduced to Tempus’ research collaborators within the Tempus Lens platform, to more seamlessly identify and analyze cohorts of interest, to quickly answer questions and develop deeper insights.

The integration of Tempus One into Lens will begin with the inclusion of user Q&A through an in-app chat assistant powered by large language models (LLMs) across the Lens platform, which will make the vast amounts of data more accessible for researchers through the enhanced support function. Users will be able to send questions directly to the chat, receive real time answers including citations and links to additional information, and provide feedback on chat response quality. The integration will also include a cohort building technology facilitated by LLMs, allowing users to more quickly size and find patient cohorts across a hundred clinical and molecular attributes within Tempus’ dataset.

“We are looking forward to expanding our Tempus One technology to our life sciences collaborators,” said Ryan Fukushima, Chief Operating Officer of Tempus. “The incorporation of our generative AI capabilities into Lens will improve the functionality of the platform for users, so they can more easily leverage our data and insights at their fingertips.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  254.00
+9.78 (4.00%)
AAPL  269.05
-1.32 (-0.49%)
AMD  259.65
+3.53 (1.38%)
BAC  53.56
+0.11 (0.21%)
GOOG  284.12
+2.30 (0.82%)
META  637.71
-10.64 (-1.64%)
MSFT  517.03
-0.78 (-0.15%)
NVDA  206.88
+4.39 (2.17%)
ORCL  257.85
-4.76 (-1.81%)
TSLA  468.37
+11.81 (2.59%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.